Saturday 17 October 2026 Export VCYT’s income statement to Excel — free account

Veracyte, Inc.

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.5%, EPS grew 3,300.0% and free cash flow grew 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

43.12 1.27 −2.86%

Follow VCYT

Alert me

Market cap: $3.6B
P/E: 29.9×
Fwd P/E: 45.1×
Dividend yield: —
F-score: 8/9
Altman Z: 21.08
Beneish M: −2.66
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 21.03

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	8	6	—	—	5	—	3	5	—	—	6	—

Insider Ownership 1.32%

Capital & Financial Ratios $m

Market Cap 3,570.00

Revenue 561.90

Net Income 114.48

Free Cash Flow 165.99

Net Debt (485.23)

Current Ratio 9.16

Debt/Equity 0.00

P/E ratio 29.94

Fwd P/E 45.10

P/S ratio 6.14

P/B ratio 2.48

Past 5Y EPS Growth —

This Y EPS Growth 7.47%

Next Y EPS Growth 1.72%

Next Y revenue growth 14.80%

Next 5Y EPS Growth 5.34%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 56.40%

10-year low 10-year high

P/B against its own 10 years 38.30%

10-year low 10-year high

EV/Sales against its own 10 years 52.97%

10-year low 10-year high

EV/FCF against its own 10 years 7.64%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	216	289	413	485
Receivables	40	47	45	54
Inventory	16	22	21	23
Other	—	—	—	—
	286	372	488	575

	2023	2024	2025	Q'26
Payables	13	9	5	8
ST’ Debt	—	—	—	—
Other	3	17	1	1
	61	79	60	63

Compound Annual Growth %

	10y	5y	3y
Sales	26.44%	34.50%	20.37%
Cash Flow	0.00%	0.00%	162.51%
Earnings	0.00%	0.00%	0.00%
Book Value	38.27%	25.46%	6.79%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	139	150	—	—	—
’25	114	130	132	141	517
’24	97	114	116	119	446
’23	82	90	90	98	361
’22	68	73	76	80	297
’21	37	55	60	67	220
’20	31	21	31	35	117

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	35	46	—	—	—
’25	5	34	45	53	136
’24	(9)	30	30	25	75
’23	(2)	17	14	16	44
’22	(9)	0	7	10	8
’21	(41)	2	(1)	8	(32)
’20	(5)	(8)	2	2	(10)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	32	43	—	—	—
’25	4	32	42	49	127
’24	(11)	27	28	20	64
’23	(3)	13	11	13	34
’22	(11)	(3)	5	8	(1)
’21	(42)	0	(3)	8	(37)
’20	(6)	(9)	1	1	(13)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.35	0.31	—	—	—
’25	0.09	(0.01)	0.24	0.51	0.82
’24	(0.02)	0.07	0.19	0.06	0.31
’23	(0.11)	(0.12)	(0.41)	(0.39)	(1.02)
’22	(0.20)	(0.13)	(0.12)	(0.05)	(0.51)
’21	(0.66)	(0.13)	(0.20)	(0.15)	(1.11)
’20	(0.24)	(0.22)	(0.08)	(0.14)	(0.66)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4.21	5.75	5.23	11.70	13.90	32.87	14.85	19.52	18.61	22.61	Analyst estimates 2026–2028 Powerpack
	High	8.45	9.80	15.50	31.18	63.55	86.03	42.95	30.52	46.00	50.71
People
People	Employees	216	246	270	354	320	761	787	815	824	755
	Revenue/emp, $m	0.30	0.29	0.34	0.34	0.37	0.29	0.38	0.44	0.54	0.68
Income, $m
Income, $m	Revenue	65	72	92	120	117	220	297	361	446	517
	Gross margin, %	60.88	60.81	64.05	69.66	64.71	66.11	59.24	63.62	66.88	70.10
	EBT	(31)	(31)	(23)	(13)	(35)	(82)	(36)	(77)	26	68
	EBT margin, %	(48.18)	(43.09)	(25.00)	(10.47)	(29.71)	(37.20)	(12.28)	(21.22)	5.78	13.19
	Net income	(31)	(31)	(23)	(13)	(35)	(76)	(37)	(74)	24	66
	Depreciation	3	4	4	4	8	20	26	27	23	18
Per share, $
Per share, $	Revenue	2.26	2.12	2.49	2.61	2.21	3.23	4.14	4.97	5.83	6.58
	Earnings	(1.09)	(0.91)	(0.62)	(0.27)	(0.66)	(1.11)	(0.51)	(1.02)	0.32	0.84
	Cash flow	(0.97)	(0.70)	(0.37)	(0.07)	(0.18)	(0.47)	0.11	0.61	0.98	1.73
	Capex	(0.15)	(0.04)	(0.05)	(0.06)	(0.05)	(0.08)	(0.12)	(0.14)	(0.15)	(0.12)
	Free cash flow	(1.12)	(0.74)	(0.42)	(0.13)	(0.24)	(0.54)	(0.01)	0.47	0.83	1.61
	Book value	2.07	1.10	2.15	5.19	7.91	16.15	15.03	14.37	15.38	16.66
	Shares, m	29	34	37	46	53	68	72	73	76	79
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	123.75	50.12
	P/S	3.48	3.17	5.06	10.70	22.18	12.74	5.47	5.51	6.79	6.40
	P/B	3.80	6.12	5.84	5.38	6.19	2.55	1.51	1.91	2.58	2.53
	EV/Sales	2.98	3.07	4.49	9.40	19.23	11.95	4.87	4.92	6.15	5.60
	EV/FCF	(6.02)	(8.75)	(26.83)	(189.60)	(180.03)	(70.87)	(1,424.06)	51.84	42.97	22.88
Cash, $m
Cash, $m	Operating cash flow	(28)	(24)	(14)	(3)	(10)	(32)	8	44	75	136
	Capex	(4)	(1)	(2)	(3)	(3)	(5)	(9)	(10)	(11)	(10)
	Free cash flow	(32)	(25)	(15)	(6)	(13)	(37)	(1)	34	64	127
Balance, $m
Balance, $m	Working capital	62	42	84	170	359	179	186	224	294	428
	Total debt	26	25	25	2	3	1	15	—	—	—
	Net debt	(34)	(9)	(53)	(158)	(347)	(176)	(179)	(216)	(289)	(413)
	Shareholders’ equity	60	37	80	239	421	1,097	1,075	1,044	1,176	1,310
Returns, %
Returns, %	ROA	(35.58)	(34.50)	(23.08)	(6.37)	(9.53)	(9.19)	(3.12)	(6.55)	2.00	4.90
	ROIC	(69.89)	(58.03)	(51.39)	(11.55)	(29.62)	(5.56)	(2.86)	(6.48)	1.14	4.03
	ROE	(56.59)	(64.05)	(39.32)	(7.89)	(10.57)	(9.96)	(3.37)	(7.02)	2.17	5.34

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
GRAL GRAIL, Inc.	$6.1B	— (loss-making)	— (loss-making)	+25.72% (above 0%: growing)	n/m	−4.95% (below 0%: shrinking)	(28.12%)	(388.89%)	Compare
RDNT RadNet, Inc.	$5.5B	— (loss-making)	279×	+24.99% (above 0%: growing)	−47.37% (below 0%: shrinking)	−43.22% (below 0%: shrinking)	14.14%	6.34%	Compare
SHC Sotera Health Company	$5.2B	31.4×	23.7×	+9.18% (above 0%: growing)	+533.33% (above 0%: growing)	+60.56% (above 0%: growing)	55.38%	33.23%	Compare
BLLN BillionToOne, Inc.	$4.9B	95.0×	99.4×	+64.40% (above 0%: growing)	n/m	+400.65% (above 0%: growing)	70.45%	5.03%	Compare
ADPT Adaptive Biotechnologies Corporation	$4.1B	— (loss-making)	— (loss-making)	+21.53% (above 0%: growing)	n/m	+42.04% (above 0%: growing)	71.82%	(22.04%)	Compare
VCYT Veracyte, Inc.	$3.6B	29.9×	45.1×	+15.49% (above 0%: growing)	n/m	+32.95% (above 0%: growing)	72.21%	15.29%
CDNA CareDx, Inc.	$3.5B	29.7×	2,967×	+52.23% (above 0%: growing)	n/m	+223.42% (above 0%: growing)	73.50%	85.81%	Compare
NEO NeoGenomics, Inc.	$2.2B	— (loss-making)	— (loss-making)	+11.21% (above 0%: growing)	n/m	−16.18% (below 0%: shrinking)	45.56%	(4.85%)	Compare
WGS GeneDx Holdings Corp.	$2.1B	— (loss-making)	— (loss-making)	+11.44% (above 0%: growing)	n/m	−585.59% (below 0%: shrinking)	68.37%	(15.25%)	Compare
Median of peers	$4.5B	31.4×	189×	+23.26%	—	+18.55%	61.87%	0.09%

All 52 Diagnostics & Research stocks →

Veracyte, Inc. (VCYT) key facts

Strength: Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
Veracyte, Inc. (VCYT) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, VCYT traded at $43.12, a market capitalization of $3.6 billion.
Return on equity was 5.34% and debt-to-equity 0.00.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 21.08 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.